Essencigliv - instructions for use, dose, side effects, contraindications

Composition of gelatin capsule shell: gelatin - 106.22 mg, glycerol - 48.93 mg, water purified - 13.6 mg, sodium benzoate E-211 - 0.25 mg, titanium dioxide E-171 - 0.22 mg, dyes: iron oxide red ( E-172) - 0.13 mg, iron oxide yellow (E-172) - 0.51 mg, iron oxide black (E-172) - 0.14 mg.

Description:

Capsules soft gelatinous oval with a seam, elastic, opaque, light brown color.

Contents of the capsules - from light yellow to dark yellow color homogeneous mass from the ointment to a more dense consistency with a peculiar smell. During storage, slight delamination of the contents of the capsules is permitted.

Pharmacotherapeutic group:hepatoprotective agent

ATX: & nbsp

A.05.B.A Preparations for the treatment of liver diseases

Pharmacodynamics:

Combined drug. Has a membrane-stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the main active substance of phospholipids) is a structural element of cellular and intracellular membranes, capable of restoring their structure and functions upon damage, providing a cytoprotective effect. Normalizes protein and lipid metabolism, prevents the loss of hepatocytes of enzymes and other active substances, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis of the liver.

Glycyrrhizinate (glycyrrhizic acid and its salts) have an anti-inflammatory effect, inhibit the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increasing the activity of natural killer cells. They have a hepatoprotective effect due to antioxidant and membrane-stabilizing activity.Potentiate the action of endogenous glucocorticosteroids, providing anti-inflammatory and antiallergic effects in non-infectious liver lesions.

When the skin is damaged due to the membrane-stabilizing and anti-inflammatory effect of the components, it limits the spread of the process and promotes regression of the disease.

Glycyrrhizinates stimulate the production of antibodies in human lymphocyte culture, proliferation of T and B lymphocytes, production γ-terferon, enhance phagocytosis of macrophages and lysozyme activity, increase the antibody titer. The stimulating effect of glycyrrhizinates on the secretion of interleukin-2 was also noted.

Pharmacokinetics:

Phosphatidylcholine

More than 90% of the ingested phospholipids are absorbed into the small intestine. Most of them are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with a current of lymph enters the blood, from where, mainly, in the high-density lipoprotein linked to the liver.Pharmacokinetics in humans was studied with the help of dinolonelephosphatidylcholine with a radioactive label - ³H (holinovaya part) and ¹⁴C (the rest of linoleic acid). Maximum concentration ³H is achieved; in 6-24 hours, amounting to 19.9% of the dose; ¹⁴C in 4-12 hours, amounting to 27.9%. the half-life of the choline component is 66 hours, the remainder of linoleic acid is 32 hours. In the stool, 2% H and 4.5% C are detected; in urine 6% H and the minimum amount ¹⁴C. Both isotopes are absorbed in the intestine by more than 90%.

Glycyrrhizic acid

After oral administration in the intestines under the influence of an enzyme β-glucuronidase, produced by bacteria of normal microflora, an active metabolite-β-glycyrrhet acid is formed from glycyrrhizic acid, which is absorbed into the systemic bloodstream. In blood β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Allocation β-glycyrrhetic acid occurs mainly with bile, in the residual quantity - with urine. According to experimental data phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and speed of its absorption by more than 2 times.

Indications:

- Fatty degeneration of the liver (hepatosis), alcoholic, toxic, including medicinal, liver damage;

- in the complex therapy of viral hepatitis, liver cirrhosis and psoriasis.

Contraindications:

- Hypersensitivity to the components of the drug;

- antiphospholipid syndrome;

- pregnancy;

- the period of breastfeeding;

- children under 12 years.

Carefully:

Portal hypertension, arterial hypertension.

If you have these diseases, you should consult your doctor before starting the drug.

Pregnancy and lactation:Do not apply.

Dosing and Administration:

Inside with food, not liquid, squeezed a small amount of liquid.

The recommended dosing regimen in adults and children over 12 years is 2 capsules 3 times a day.

Duration of use can be up to 6 months, on average - 3 months.

Side effects:

The drug is well tolerated, side effects develop very rarely.

Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.

From the cardiovascular system: transient (transient) increase in blood pressure, peripheral edema.

On the part of the digestive system: dyspepsia (belching, nausea, bloating), abdominal discomfort.

If these symptoms occur, stop taking the medication and consult a doctor.

Overdose:

No cases of overdose have been reported.

Glycyrrhizic acid, which is part of the drug, can cause a pseudocorticosteroid effect in large doses, which consists in an increase in the level of glucocorticoids and mineralocorticoids in the blood. This leads to a delay in sodium and a decrease in potassium in the body, and, as a result, an increase in blood pressure, fluid retention in the body.

Glycyrate, used internally for a long period (more than 6 weeks), can cause symptoms of intoxication: headache, lethargy, high blood pressure, swelling, removal of potassium from the body.

Interaction:

Glycyrrhizic acid, which is part of the drug, is a synergist of corticosteroid hormones, it enhances and prolongs their effect.

Special instructions:

Essencigliv contains the active ingredient of the trisodium salt of glycyrrhizic acid (35 mg per capsule).

Glycyrrhizic acid (glycyrate) is isolated from the extract of licorice root (licorice), refers to steroid saponins.

The use of glycyrrhizic acid in doses exceeding the therapeutic dose leads to serious side effects.

Effect on the ability to drive transp. cf. and fur:

The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Capsules, 35 mg + 65 mg.

Packaging:

10 capsules per contour cell packaging made of polyvinylchloride film and aluminum foil printed lacquered.

For 5 contour squares, together with the instruction for use, they are placed in packs of cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-003507

Date of registration:16.03.2016

Expiration Date:16.03.2021

The owner of the registration certificate:MINSKINTERKAPS, UP MINSKINTERKAPS, UP Republic of Belarus

Manufacturer: & nbsp

MINSKINTERKAPS, UP Republic of Belarus

Representation: & nbspMINSKINTERKAPS MINSKINTERKAPS Republic of Belarus

Information update date: & nbsp07.08.2016

Illustrated instructions

Instructions

Essenciglive (Essentigliv)